Division of Cardiology, Department of Medicine, University Malaya Medical Centre, Kuala Lumpur, Selangor, Malaysia
Department of Medicine, Hospital Queen Elizabeth, Kota Kinabalu, Sabah, Malaysia.
BMJ Open. 2021 Jan 21;11(1):e039869. doi: 10.1136/bmjopen-2020-039869.
To identify the prevalence of stage B heart failure (SBHF) in patients with type 2 diabetes mellitus (T2DM) with no history of cardiovascular disease (CVD).
Observational study.
A single-centre study in which eligible patients were recruited from T2DM clinic. Following consent, patients completed a questionnaire and underwent physical examinations. Patients had blood drawn for laboratory investigations and had a transthoracic echocardiography.
A total of 305 patients who were not known to have CVD were recruited. Patients with deranged liver function tests and end stage renal failure were excluded.
Echocardiographic parameters such as left ventricular ejection fraction, left ventricular mass index (LVMI), left ventricular hypertrophy, left atrial enlargement and diastolic function were examined.
A total of 305 patients predominantly females (65%), with mean body mass index of 27.5 kg/m participated in this study. None of them had either a history or signs and symptoms of CVD. Seventy-seven percent of patients had a history of hypertension and 83% of this study population had T2DM for more than 10 years. Mean HbA1c of 8.3% was recorded. Almost all patients were taking metformin. Approximately, 40% of patients were on newer anti-T2DM agents such as sodium-glucose cotransporter-2 and dipeptidyl peptidase 4 inhibitors. Fifty-seven percent (n=174) of the study population had SBHF at the time of study: diastolic dysfunction, increased LVMI and increased left atrial volume index (LAVI) were noted in 51 patients (17%), 128 patients (42%) and 98 patients (32%), respectively. Thirty-seven patients (12%) had both increase LVMI and LAVI.
Our study has revealed a high prevalence of SBHF in T2DM patients without overt cardiac disease in Malaysia that has one of the highest prevalence of TDM in the world.
确定无心血管疾病(CVD)病史的 2 型糖尿病(T2DM)患者中心力衰竭 B 期(SBHF)的患病率。
观察性研究。
在 T2DM 诊所招募合格患者的单中心研究。征得同意后,患者完成了一份问卷并接受了体格检查。为实验室检查采集了患者的血液,并进行了经胸超声心动图检查。
共招募了 305 名未确诊为 CVD 的患者。排除肝功能检查异常和终末期肾衰竭的患者。
检查左心室射血分数、左心室质量指数(LVMI)、左心室肥厚、左心房扩大和舒张功能等超声心动图参数。
共有 305 名女性(65%)患者参与了这项研究,平均体重指数为 27.5kg/m。他们均无 CVD 病史或症状和体征。77%的患者有高血压病史,83%的患者患有 T2DM 超过 10 年。记录的平均 HbA1c 为 8.3%。几乎所有患者都在服用二甲双胍。大约 40%的患者正在服用新型抗 T2DM 药物,如钠-葡萄糖共转运蛋白-2 和二肽基肽酶 4 抑制剂。在研究时,57%(n=174)的研究人群患有 SBHF:51 名患者(17%)存在舒张功能障碍,128 名患者(42%)存在 LVMI 增加,98 名患者(32%)存在左心房容积指数(LAVI)增加,37 名患者(12%)同时存在 LVMI 和 LAVI 增加。
我们的研究表明,在马来西亚,无明显心脏疾病的 T2DM 患者中 SBHF 的患病率很高,而马来西亚是世界上 T2DM 患病率最高的国家之一。